Literature DB >> 17895411

Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?

Silvia Bopp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17895411      PMCID： PMC2001031          DOI： 10.1136/bjo.2007.120303

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  6 in total

1.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; Andrew A Moshfeghi; Carmen A Puliafito
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2005 Jul-Aug

2.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

Authors:  U Chakravarthy; A P Adamis; E T Cunningham; M Goldbaum; D R Guyer; B Katz; Manju Patel
Journal:  Ophthalmology       Date:  2006-07-07       Impact factor: 12.079

5.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

Authors:  Anne E Fung; Geeta A Lalwani; Philip J Rosenfeld; Sander R Dubovy; Stephan Michels; William J Feuer; Carmen A Puliafito; Janet L Davis; Harry W Flynn; Maria Esquiabro
Journal:  Am J Ophthalmol       Date:  2007-04       Impact factor: 5.258

6.  Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions.

Authors:  Anja Lux; Helene Llacer; Florian M A Heussen; Antonia M Joussen
Journal:  Br J Ophthalmol       Date:  2007-05-30       Impact factor: 4.638
  6 in total
  4 in total

1.  Enhancing RPE Cell-Based Therapy Outcomes for AMD: The Role of Bruch's Membrane.

Authors:  Janosch P Heller; Keith R Martin
Journal:  Transl Vis Sci Technol       Date:  2014-07-03       Impact factor: 3.283

2.  Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13.

Authors:  Yeoun-Hee Kim; Jae-Chang Jung; Sang Il Gum; Su-Bin Park; Jin Yeul Ma; Yong Il Kim; Kyoo Won Lee; Young Jeung Park
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

3.  Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization.

Authors:  Alessandra Puddu; Roberta Sanguineti; Arianna Durante; Massimo Nicolò; Giorgio L Viviani
Journal:  Mol Vis       Date:  2012-10-11       Impact factor: 2.367

4.  Cytoprotective Effects of Natural Highly Bio-Available Vegetable Derivatives on Human-Derived Retinal Cells.

Authors:  Ingrid Munia; Laurent Gafray; Marie-Agnès Bringer; Pablo Goldschmidt; Lil Proukhnitzky; Nathalie Jacquemot; Christine Cercy; Khaoula Ramchani Ben Otman; Marie Hélène Errera; Isabelle Ranchon-Cole
Journal:  Nutrients       Date:  2020-03-24       Impact factor: 5.717
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.